Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Thoracic 3Lymphoid 1Gynecologic 1Breast 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × XL147 × Thoracic × Clear all
NCT00704392 2015-08-20

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors

Exelixis

Phase 1 Withdrawn
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00756847 2013-04-10

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Sanofi

Phase 1 Completed
52 enrolled
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00692640 2012-03-23

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors

Sanofi

Phase 1 Completed
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡